Key Financial Performance (FY 2025-26)

Revenue and Profitability

  • Revenue from operations: ₹4,747.27 lakh (₹47.47 crore), declined 5.4% from FY25 (₹5,019.52 lakh)
  • EBITDA: ₹363.45 lakh (₹3.63 crore) with EBITDA margin of 7.66%
  • Profit Before Tax: ₹303.23 lakh (₹3.03 crore)
  • Profit After Tax: ₹220.17 lakh (₹2.20 crore), improved from net loss of ₹97.87 lakh in FY25
  • Earnings Per Share: ₹2.92 (basic and diluted), improved from loss per share of ₹1.32 in FY25

Balance Sheet Position

  • Net Worth: ₹972.81 lakh, increased by over 50% from previous year
  • Total Assets: ₹2,455.12 lakh
  • Long-term debt: ₹3.00 lakh (near-zero debt position)
  • Current Ratio: 1.32 (improved from 0.95 in FY25)
  • Debt-Equity Ratio: 0.13

Cash Flow

  • Net Cash Flow from Operating Activities: ₹171.47 lakh (positive for second consecutive year)
  • Cash and Cash Equivalents: ₹285.98 lakh at year-end

Operational Highlights

Field Force and Network

  • Medical Representatives: 150 (rationalized from 165 in FY25)
  • States Covered: 13
  • Districts Covered: 224 (rationalized from 240)
  • Doctors Engaged: 25,000+
  • Retail Outlets: 22,000+
  • Stockists: 385 (rationalized from 400)

Productivity Metrics

  • Per-Territory Productivity (PCPM): ₹2.50 lakh, improved from ₹2.47 lakh in FY25
  • 39% improvement in PCPM over three years from ₹1.80L in FY23

Brand Performance

  • TYNOL: ₹5.75 crore value with 14% growth, 5-year CAGR of 19.3%, targeting ₹10 crore in FY27
  • ACOLATE: ₹8.60 crore value, impacted by regulatory changes on fixed-dose combinations
  • New Brands: LASOKID grew ~380%, NOVOTER grew 136%, HYTERCE contributed ₹52 lakh in first full year

Manufacturing Operations

  • Contract manufacturing model with WHO-GMP certified partners
  • Full IP ownership of all formulations and product specifications
  • In-house quality assurance team conducting independent audits
  • Long-term contracts ensuring supply reliability and preferential pricing

Annual General Meeting Details

  • Date: Friday, 21st August 2026
  • Time: 12:00 noon
  • Mode: Video Conferencing/Other Audio-Visual Means
  • E-voting period: 18th August 2026 (9:00 a.m.) to 20th August 2026 (5:00 p.m.)
  • Record date: 14th August 2026

AGM Agenda Items

Ordinary Business

1. Adoption of Audited Standalone Financial Statements for FY 2025-26

2. Re-appointment of Mr. Natwarbhai Prajapati as Director liable to retire by rotation

Special Business

3. Re-appointment of Mr. Aalap Prajapati as Managing Director & CEO for 3 years (28 October 2026 to 27 October 2029)

4. Ratification of remuneration of M/s. K V M & Co., Cost Auditors for FY 2026-27 at ₹50,000

Corporate Actions

  • Preferential allotment of 3,71,000 equity shares to Mr. Aalap Prajapati on 16 December 2025 at ₹37.70 per share
  • Promoter holding increased to 40.03% (up 3%)
  • Shares listed on BSE on 25 February 2026

Auditor Reports

  • Statutory Auditors: Shah Doshi Patel & Associates LLP - Unmodified opinion
  • Secretarial Auditor: Pinakin Shah & Co. - Unmodified secretarial audit report
  • Cost Auditor: M/s. K V M & Co. appointed for FY 2026-27

Key Management

  • Managing Director & CEO: Mr. Aalap Prajapati (DIN: 08088327)
  • Whole Time Director: Mr. Natwarbhai P. Prajapati (DIN: 00031187)
  • Whole Time Director: Mr. Amritbhai P. Prajapati (DIN: 00699001)
  • Chief Financial Officer: Mr. Bhagirath Ramhit Maurya
  • Company Secretary: Ms. Ashka Solanki (from 1 September 2025)

Dividend

  • No dividend recommended for FY26 to conserve resources for operational requirements